Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: A retrospective study

European Journal of Haematology

Volumn 85, Issue 1, 2010, Pages 36-42

  Ricchi, Paolo ^a   Ammirabile, Massimiliano ^a   Spasiano, Anna ^a   Costantini, Silvia ^a   Cinque, Patrizia ^a   Di Matola, Tiziana ^b   Pagano, Leonilde ^a   Prossomariti, Luciano ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b Centro Traumatologico Ortopedico ASLNA1   (Italy)

Author keywords

Agranulocytosis; Iron chelator; Iron overload; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THALASSEMIA; THALASSEMIA MAJOR; WEIGHT GAIN;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED; MYOCARDIUM; PYRIDONES; RETROSPECTIVE STUDIES; SIDEROPHORES; YOUNG ADULT;

EID: 77953851155     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01447.x     Document Type: Article

References (12)

1. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998 103 : 361 644.
2. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subsutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. The Lancet 2002 360 : 516 520.
3. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003 121 : 187 189.
4. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, Tzouvara E, Bourantas KL. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Am J Hematol 2004 5 : 475 479.
5. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006 85 : 315 319.
6. El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience Ann Hematol 2008 87 : 545 550.
7. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006 36 : 21 5.
8. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R. Combined therapy with deferiprone and desfoerrioxamine in thalassemia major. Haematologica 2005 90 : 1163 1168.
9. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007 115 : 1876 1884.
10. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008 10 : 12.
11. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 107 : 3738 3744.
12. Cogliandro T, Derchi G, Mancuso L, et al. Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown) 2008 9 : 515 525.